Actively Recruiting
Absorption of Iron From Stabilized Lactoferrin: A Study in Women With Iron Deficiency
Led by Nicole Stoffel · Updated on 2026-02-12
45
Participants Needed
1
Research Sites
10 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Lactoferrin (LF) is a natural iron-binding protein found in milk. It exists either in an iron-free state (apo-LF) or bound to iron (holo-LF). Whether LF binds iron to facilitate its absorption and/or to sequester iron from potential enteropathogens remains uncertain. However, while LF is a promising tool for treating iron deficiency, it is sensitive to heat during food processing and to the acidic environment of the human stomach. This degradation often causes LF to lose its functional properties before it can promote iron absorption effectively. This study aims to evaluate whether encapsulating apo-LF (either alone or in combination with iron) can protect LF from digestion and enhance iron absorption. Using a randomized, crossover design, different encapsulation methods will be compared to determine which results in the highest iron absorption in women with iron deficiency. All test compounds will be labeled with stable iron isotopes. Participants will consume the labeled compounds with a test meal or water in a randomized order, allowing for within subject comparisons. Fractional iron absorption will be measured 17 days after administration via the incorporation of labeled iron into red blood cells.
CONDITIONS
Official Title
Absorption of Iron From Stabilized Lactoferrin: A Study in Women With Iron Deficiency
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Serum ferritin less than 45 g/L indicating iron depletion
- Body weight less than 70 kg
- Body mass index between 18.5 and 24.9 kg/m2 (normal weight)
- Hemoglobin greater than 120 g/L (nonanemic)
- C-reactive protein less than 5 mg/L (no inflammation)
You will not qualify if you...
- Pregnant or lactating women
- Strict vegans
- Smoking more than 1 cigarette per week
- Gastrointestinal or metabolic disorders affecting iron absorption or metabolism
- Use of medication affecting iron metabolism (oral contraceptives allowed)
- Use of vitamin or mineral supplements within 2 weeks before and during the study
- Blood transfusion, donation, or significant blood loss within 4 months
- Inability to follow study procedures or having a major illness
- Participation in another study with investigational drug within 30 days before or during this study
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
ETH Zurich, Laboratory of Clinical Biopharmacy
Zurich, Switzerland, 8092
Actively Recruiting
Research Team
S
Salome Häcki, MSc
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
RANDOMIZED
Model
CROSSOVER
Primary Purpose
OTHER
Number of Arms
9
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here